Mount Sinai Medical Center

Mount Sinai, United States

Mount Sinai Medical Center

Mount Sinai, United States
SEARCH FILTERS
Time filter
Source Type

Morrisville, NC, May 16, 2017 (GLOBE NEWSWIRE) -- The American Society of Echocardiography (ASE) will host its 28th Annual Scientific Sessions, June 2-6, 2017, at the Baltimore Convention Center, Baltimore, Maryland. The program includes innovative learning opportunities from the basics of clinical imaging, to the most sophisticated advances in microbubble gene delivery, to the determination of the best use of echo in value-driven healthcare. The aim is to translate core concepts and new ideas into applicable frameworks. The Advance Program is online and can be downloaded at ASEScientificSessions.org. In addition, the ASE Courses App is continuously updated with detailed session information. Attendance at this four day conference can fulfill certification and accreditation requirements for general medical education or echo-specific CME/MOC content needs. Geoffrey A. Rose, MD, FASE, from Sanger Heart & Vascular Institute Charlotte, NC, is the program chair and has selected international cardiovascular experts to present to an audience of over 2,000 participants. ASE 2017 has a number of sessions that provide a deeper dive into key areas including cardio-oncology, structural heart disease, and critical care echocardiography. The Value of Echo Summit taking place on Monday, June 5, 10:15 AM - 2:45 PM, will explore the cataclysmic changes in the U.S. healthcare system and provide expert opinions on how best to navigate and thrive in this new environment. This special Summit is focused on helping the entire cardiovascular ultrasound community understand how their practice is impacted. Registered attendees are invited to bring their hospital administrators and service line leaders to this session free of charge. Another feature of the ASE Scientific Sessions is the 2nd annual Echovation Challenge, a competition Monday, June 5 to showcase novel ideas that have the capacity to enhance the workflow efficiency of cardiovascular ultrasound laboratories while maintaining excellence in patient care. Five finalists will present their approaches to streamlining diagnostics for improved medical decision making. Susan E. Wiegers, MD, FASE, Senior Associate Dean of Faculty Affairs at Lewis Katz School of Medicine at Temple University, Philadelphia, PA, and immediate past president of ASE, will present the 28th Annual Edler Lecture “The Point of Care” on Sunday, June 4, 7:30-9:30 AM. “The Evolution of Contrast Echocardiography: A Journey From Diagnostic to Therapeutic Application,” will be presented by Howard M. Leong-Poi, MD, FASE, Head of the Division of Cardiology at St. Michael’s Hospital and Associate Professor of Medicine at the University of Toronto, Toronto, ON, Canada, as the 18th Annual Feigenbaum Lecture, on Monday afternoon during the Young Investigator’s Award competition. Valentin Fuster, MD, PhD, Director of the Zena and Michael A. Wiener Cardiovascular Institute at Mount Sinai Medical Center, New York, NY, and one of the most prominent cardiologists in the world, is a guest lecturer and co-chair of the Vascular Council’s symposium “The Coming Storm: Atherosclerosis Imaging” on Saturday afternoon. ASE 2017 also boasts the largest echo-specific gathering in the world featuring nearly 50 exhibitors presenting new concepts, technology, devices, and research. This year we have a number of first time vendors. Participants can take part in interactive demonstrations to gain firsthand knowledge of how devices work and how they will benefit practices or institutions. Top experts in the field will make daily presentations in the Science & Technology Theater and in “chalk talks” held on the show floor. Nearly 400 posters will be presented featuring cutting-edge research on the latest advances in cardiovascular ultrasound or clinical cases illustrating evolutions in patient care. Moderated poster presentations will take place on Sunday and Monday. ASE is pleased to offer qualified members of the media a complimentary registration. We can help you present interesting news and developments in cardiac ultrasound technology.  Please contact Angie Porter at aporter@asecho.org if you need any additional information, would like to register to cover the event, or if you would like to arrange interviews with our expert faculty or ASE leadership. Onsite media registration is available, but, if possible we would like to prepare for your coverage in advance. As the largest global organization for cardiovascular ultrasound imaging, the American Society of Echocardiography (ASE) is the leader and advocate, setting practice standards and guidelines. Comprised of over 17,000 physicians, sonographers, nurses, and scientists, ASE is a strong voice providing guidance, expertise, and education to its members. The Society has a commitment to improving the practice of ultrasound and imaging of the heart and cardiovascular system for better patient outcomes. For more information about ASE, visit ASEcho.org or the ASE Scientific Sessions visit ASEScientificSessions.org. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/bd996363-703c-426c-b07b-e64278f5da0a


Morrisville, NC, May 16, 2017 (GLOBE NEWSWIRE) -- The American Society of Echocardiography (ASE) will host its 28th Annual Scientific Sessions, June 2-6, 2017, at the Baltimore Convention Center, Baltimore, Maryland. The program includes innovative learning opportunities from the basics of clinical imaging, to the most sophisticated advances in microbubble gene delivery, to the determination of the best use of echo in value-driven healthcare. The aim is to translate core concepts and new ideas into applicable frameworks. The Advance Program is online and can be downloaded at ASEScientificSessions.org. In addition, the ASE Courses App is continuously updated with detailed session information. Attendance at this four day conference can fulfill certification and accreditation requirements for general medical education or echo-specific CME/MOC content needs. Geoffrey A. Rose, MD, FASE, from Sanger Heart & Vascular Institute Charlotte, NC, is the program chair and has selected international cardiovascular experts to present to an audience of over 2,000 participants. ASE 2017 has a number of sessions that provide a deeper dive into key areas including cardio-oncology, structural heart disease, and critical care echocardiography. The Value of Echo Summit taking place on Monday, June 5, 10:15 AM - 2:45 PM, will explore the cataclysmic changes in the U.S. healthcare system and provide expert opinions on how best to navigate and thrive in this new environment. This special Summit is focused on helping the entire cardiovascular ultrasound community understand how their practice is impacted. Registered attendees are invited to bring their hospital administrators and service line leaders to this session free of charge. Another feature of the ASE Scientific Sessions is the 2nd annual Echovation Challenge, a competition Monday, June 5 to showcase novel ideas that have the capacity to enhance the workflow efficiency of cardiovascular ultrasound laboratories while maintaining excellence in patient care. Five finalists will present their approaches to streamlining diagnostics for improved medical decision making. Susan E. Wiegers, MD, FASE, Senior Associate Dean of Faculty Affairs at Lewis Katz School of Medicine at Temple University, Philadelphia, PA, and immediate past president of ASE, will present the 28th Annual Edler Lecture “The Point of Care” on Sunday, June 4, 7:30-9:30 AM. “The Evolution of Contrast Echocardiography: A Journey From Diagnostic to Therapeutic Application,” will be presented by Howard M. Leong-Poi, MD, FASE, Head of the Division of Cardiology at St. Michael’s Hospital and Associate Professor of Medicine at the University of Toronto, Toronto, ON, Canada, as the 18th Annual Feigenbaum Lecture, on Monday afternoon during the Young Investigator’s Award competition. Valentin Fuster, MD, PhD, Director of the Zena and Michael A. Wiener Cardiovascular Institute at Mount Sinai Medical Center, New York, NY, and one of the most prominent cardiologists in the world, is a guest lecturer and co-chair of the Vascular Council’s symposium “The Coming Storm: Atherosclerosis Imaging” on Saturday afternoon. ASE 2017 also boasts the largest echo-specific gathering in the world featuring nearly 50 exhibitors presenting new concepts, technology, devices, and research. This year we have a number of first time vendors. Participants can take part in interactive demonstrations to gain firsthand knowledge of how devices work and how they will benefit practices or institutions. Top experts in the field will make daily presentations in the Science & Technology Theater and in “chalk talks” held on the show floor. Nearly 400 posters will be presented featuring cutting-edge research on the latest advances in cardiovascular ultrasound or clinical cases illustrating evolutions in patient care. Moderated poster presentations will take place on Sunday and Monday. ASE is pleased to offer qualified members of the media a complimentary registration. We can help you present interesting news and developments in cardiac ultrasound technology.  Please contact Angie Porter at aporter@asecho.org if you need any additional information, would like to register to cover the event, or if you would like to arrange interviews with our expert faculty or ASE leadership. Onsite media registration is available, but, if possible we would like to prepare for your coverage in advance. As the largest global organization for cardiovascular ultrasound imaging, the American Society of Echocardiography (ASE) is the leader and advocate, setting practice standards and guidelines. Comprised of over 17,000 physicians, sonographers, nurses, and scientists, ASE is a strong voice providing guidance, expertise, and education to its members. The Society has a commitment to improving the practice of ultrasound and imaging of the heart and cardiovascular system for better patient outcomes. For more information about ASE, visit ASEcho.org or the ASE Scientific Sessions visit ASEScientificSessions.org. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/bd996363-703c-426c-b07b-e64278f5da0a


Morrisville, NC, May 16, 2017 (GLOBE NEWSWIRE) -- The American Society of Echocardiography (ASE) will host its 28th Annual Scientific Sessions, June 2-6, 2017, at the Baltimore Convention Center, Baltimore, Maryland. The program includes innovative learning opportunities from the basics of clinical imaging, to the most sophisticated advances in microbubble gene delivery, to the determination of the best use of echo in value-driven healthcare. The aim is to translate core concepts and new ideas into applicable frameworks. The Advance Program is online and can be downloaded at ASEScientificSessions.org. In addition, the ASE Courses App is continuously updated with detailed session information. Attendance at this four day conference can fulfill certification and accreditation requirements for general medical education or echo-specific CME/MOC content needs. Geoffrey A. Rose, MD, FASE, from Sanger Heart & Vascular Institute Charlotte, NC, is the program chair and has selected international cardiovascular experts to present to an audience of over 2,000 participants. ASE 2017 has a number of sessions that provide a deeper dive into key areas including cardio-oncology, structural heart disease, and critical care echocardiography. The Value of Echo Summit taking place on Monday, June 5, 10:15 AM - 2:45 PM, will explore the cataclysmic changes in the U.S. healthcare system and provide expert opinions on how best to navigate and thrive in this new environment. This special Summit is focused on helping the entire cardiovascular ultrasound community understand how their practice is impacted. Registered attendees are invited to bring their hospital administrators and service line leaders to this session free of charge. Another feature of the ASE Scientific Sessions is the 2nd annual Echovation Challenge, a competition Monday, June 5 to showcase novel ideas that have the capacity to enhance the workflow efficiency of cardiovascular ultrasound laboratories while maintaining excellence in patient care. Five finalists will present their approaches to streamlining diagnostics for improved medical decision making. Susan E. Wiegers, MD, FASE, Senior Associate Dean of Faculty Affairs at Lewis Katz School of Medicine at Temple University, Philadelphia, PA, and immediate past president of ASE, will present the 28th Annual Edler Lecture “The Point of Care” on Sunday, June 4, 7:30-9:30 AM. “The Evolution of Contrast Echocardiography: A Journey From Diagnostic to Therapeutic Application,” will be presented by Howard M. Leong-Poi, MD, FASE, Head of the Division of Cardiology at St. Michael’s Hospital and Associate Professor of Medicine at the University of Toronto, Toronto, ON, Canada, as the 18th Annual Feigenbaum Lecture, on Monday afternoon during the Young Investigator’s Award competition. Valentin Fuster, MD, PhD, Director of the Zena and Michael A. Wiener Cardiovascular Institute at Mount Sinai Medical Center, New York, NY, and one of the most prominent cardiologists in the world, is a guest lecturer and co-chair of the Vascular Council’s symposium “The Coming Storm: Atherosclerosis Imaging” on Saturday afternoon. ASE 2017 also boasts the largest echo-specific gathering in the world featuring nearly 50 exhibitors presenting new concepts, technology, devices, and research. This year we have a number of first time vendors. Participants can take part in interactive demonstrations to gain firsthand knowledge of how devices work and how they will benefit practices or institutions. Top experts in the field will make daily presentations in the Science & Technology Theater and in “chalk talks” held on the show floor. Nearly 400 posters will be presented featuring cutting-edge research on the latest advances in cardiovascular ultrasound or clinical cases illustrating evolutions in patient care. Moderated poster presentations will take place on Sunday and Monday. ASE is pleased to offer qualified members of the media a complimentary registration. We can help you present interesting news and developments in cardiac ultrasound technology.  Please contact Angie Porter at aporter@asecho.org if you need any additional information, would like to register to cover the event, or if you would like to arrange interviews with our expert faculty or ASE leadership. Onsite media registration is available, but, if possible we would like to prepare for your coverage in advance. As the largest global organization for cardiovascular ultrasound imaging, the American Society of Echocardiography (ASE) is the leader and advocate, setting practice standards and guidelines. Comprised of over 17,000 physicians, sonographers, nurses, and scientists, ASE is a strong voice providing guidance, expertise, and education to its members. The Society has a commitment to improving the practice of ultrasound and imaging of the heart and cardiovascular system for better patient outcomes. For more information about ASE, visit ASEcho.org or the ASE Scientific Sessions visit ASEScientificSessions.org. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/bd996363-703c-426c-b07b-e64278f5da0a


The paper, SPX-101 Is A Novel ENaC-Targeted Therapeutic for Cystic Fibrosis That Restores Mucus Transport 1, investigates the in vitro and in vivo efficacy of SPX-101, a peptide mimetic of SPLUNC1's natural regulation of ENaC activity. SPX-101 is an inhaled peptide with a novel, biological mechanism that regulates epithelial sodium channel (ENaC) density in the airway.  The drug is designed to restore a cellular pathway in the lung that promotes airway hydration and mucociliary clearance, which are dysfunctional in CF. The mechanism of action of SPX-101 is independent of the genetic mutations that cause CF, which makes it a potential therapy for all CF patients. The authors used biochemical approaches to demonstrate that SPX-101 binds specifically to ENaC, but not structurally similar proteins, inducing ENaC internalization in human bronchial epithelial cells from healthy and CF donors. Removal of ENaC from the plasma membrane caused a significant reduction in amiloride sensitive current and increased hydration of the airway epithelial cell cultures.  When tested in vivo, they demonstrated that SPX-101 significantly increased survival of βENaC transgenic mice and increased mucus transport in mouse and sheep models of CF lung disease.  The authors concluded that via this unique biological mechanism of action in removing ENaC from the cell surface, SPX-101 promotes a durable inhibition of sodium absorption resulting in increased mucus transport. "We are honored to have the opportunity to share our work on SPX-101 with the research and clinical community through this publication in The Blue Journal," said Timm Crowder, PhD, Senior Vice President, Technical Operations for Spyryx and one of the authors of the paper. "It highlights the opportunity for a treatment approach that extends beyond mutation specific therapies, targeting treatment for all CF patients. The strong preclinical data supporting SPX-101's ability to promote airway hydration and mucociliary clearance suggest high potential for our product to deliver clinically meaningful benefit, which we will thoroughly investigate in our Phase 2 study beginning mid-2017." About Cystic Fibrosis CF is an autosomal recessive genetic disorder affecting approximately 75,000 individuals worldwide.  The disease is caused by mutations in the gene for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. CF profoundly affects the lungs and respiratory tract and is characterized by dehydration of the airway surface, resulting in reduced mucus clearance, the lung's principle mechanism for maintaining a clean environment. The mucus becomes thick and sticky, progressively accumulating into obstructions that block airflow and result in recurrent colonization of the airways by viruses and bacteria.  These pathogens lead to frequent, acute lung infections, chronic inflammation, exacerbations, and impaired lung function. The long-term result of the disease, is progressive, permanent tissue damage and scarring (fibrosis) in the lung.  No cure for cystic fibrosis is known, although several treatments have been approved to address the underlying cause of the disease in some patients. Despite currently available treatment, the median age of survival for CF patients is approximately 40 years of age. About Spyryx Biosciences Spyryx Biosciences is a privately held, clinical-stage biopharmaceutical company developing innovative therapeutics to address severe lung diseases. Spyryx's lead clinical candidate, SPX-101, is a novel treatment for cystic fibrosis that has successfully completed a Phase 1 study in healthy volunteers and is advancing into Phase 2 in CF patients. The product has demonstrated a robust ability to restore mucociliary clearance in animal models of the disease and has the potential to improve lung function in all cystic fibrosis patients independent of their CFTR mutation. The Spyryx leadership team and scientific staff have extensive experience in the development of respiratory medicines and work closely with a broad group of clinical and scientific experts in the pulmonary field. Spyryx is funded by a first tier syndicate of life science investors, including Canaan Partners, 5AM Ventures and Hatteras Venture Partners. Further information regarding Spyryx Biosciences is available at www.spyryxbio.com. 1SPX-101 is a novel ENaC-targeted therapeutic for cystic fibrosis that restores mucus transport 1Spyryx Biosciences, 801-10 Capitola Dr, Durham, NC, 27713. 2Department of Research Mount Sinai Medical Center, Miami Beach, FL, 33140. 3Marsico Lung institute and Department of Cell Biology and Physiology, 111 Mason Farm Rd, The University of North Carolina, Chapel Hill, NC, 27599-7248. #Current Address: Duke University Medical Center, Department of Medicine, Durham, NC 27710 To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/the-american-journal-of-respiratory-and-critical-care-medicine-publishes-study-of-spyryx-biosciences-spx-101-a-novel-enac-targeted-therapeutic-for-cystic-fibrosis-that-restores-mucus-transport-300454404.html


Francis D. Baudry, MD, Psychiatrist and Psychoanalyst with his own practice, and affiliated with Mount Sinai Medical Center, and on the faculty of the New York Psychoanalytic Institute where he is a Training and Supervising analyst has been named a 2017 Top Doctor in New York City, New York. Top Doctor Awards is dedicated to selecting and honoring those healthcare practitioners who have demonstrated clinical excellence while delivering the highest standards of patient care. He is also a member of the Soldier’s project, an organization dedicated to giving free mental health care to veterans and their families. Dr. Francis D. Baudry was born in France and speaks fluent French and treats patients in both French and English. He is a vastly experienced psychiatrist, having been in practice for more than six decades. His long and successful career in psychiatry began in 1955, when he graduated from the New York University School of Medicine. After an internship at the Albert Einstein-Montefiore Medical Center, Dr. Baudry returned to New York University to complete his residency. Dr. Baudry is board certified by the American Board of Psychiatry and Neurology, and is renowned across New York and beyond as a specialist in psychiatry and in psychoanalysis. He has lectured widely in England, France, Italy and Israel. With his wealth of experience to call upon, Dr. Baudry diagnoses and treats a wide range of conditions, from anxiety and depressive disorder, to post traumatic stress disorder, psychosomatic conditions and  borderline personality disorders. He also has a special interest in issues of creativity and its inhibitions both in literature and in the visual arts. Dr. Baudry has written many papers on topics ranging from liaison psychiatry to the art of supervision, character issues, the analytic encounter, applied psychoanalysis ( visual arts , poetry, novels and theater). He is also quite knowledgeable in French psychoanalysis and has written on the contribution of Andre Green.He is always happy to help mentor and advise less experienced colleagues and his dedication and commitment makes Dr. Francis D. Baudry a very worthy winner of a 2017 Top Doctor Award. Top Doctor Awards specializes in recognizing and commemorating the achievements of today’s most influential and respected doctors in medicine. Our selection process considers education, research contributions, patient reviews, and other quality measures to identify top doctors.


News Article | May 10, 2017
Site: www.marketwired.com

MIAMI, FL--(Marketwired - May 10, 2017) - Omni Health, Inc., ( : OMHE), a vertically integrated healthcare company dedicated to the development of pharmaceutical, anti-aging products, and cannabis biotech engineering, announced today the formation of its Scientific Advisory Board (SAB) and appointment of Dr. Arkady Uryash MD, PhD. as its inaugural member. The Scientific Advisory Board will serve as a vital strategic network of scientific, medical and clinical experts to Omni Health as the company prepares to bring, acquire and develop innovative products into its pipeline. "The formation of this Scientific Advisory Board demonstrates our commitment to robust science and thoughtful product development strategies," says Omni Health CEO Andrey Soloviev. He went on to say, "We are honored to welcome Dr. Uryash MD, PhD. as an inaugural member and will be expanding this Board with an elite group of industry, academic, and government experts to provide a valued combination of scientific guidance and business acumen encompassing biotech and pharmaceuticals. I look forward to working closely with this Board as each member brings a unique set of skills and experience to help shape a successful future for Omni Health." Dr. Arkady Uryash, MD, PhD. Dr. Uryash is the Director of Biomedical Research for the internship program of Mount Sinai Medical Center and Associate Professor of Cardiology and Vascular Biology for Mount Sinai Center in Miami. As an experienced Director of Research and Development, Dr. Uryash is knowledgeable in U.S. Food and Drug Administration (FDA) regulation, research and development, and clinical trials. Dr. Uryash has previously served as CEO of a biotech company and is experienced in the management of biotech company operations, interdisciplinary team recruitment, and intellectual property. He has published numerous articles in peer-review journals and is a recipient of several academic awards and honors. "The formation of our Scientific Advisory Board serves as a clear endorsement, bringing merit to the scientific, medical and commercial potential of our vision to take Omni Health to the next level, which we believe could be transformative for medicine and for the company," concluded Andrey Soloviev. For more information on Omni Health, visit the company's new website at www.OmniHealth.md About Omni Health Inc. Omni Health, Inc., ( : OMHE) is a 40 year old vertically integrated healthcare company dedicated to the development of pharmaceutical, anti-aging products, and cannabis biotech engineering with a robust pipeline of new products and breakthrough innovation. Safe Harbor Statement Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, and future product commercialization; and the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies.


Tomer Y.,Mount Sinai Medical Center | Tomer Y.,James ters Va Medical Center
Annual Review of Pathology: Mechanisms of Disease | Year: 2014

Recent advances in our understanding of genetic-epigenetic interactions have unraveled new mechanisms underlying the etiology of complex autoimmune diseases. Autoimmune thyroid diseases (AITDs) are highly prevalent, affecting 1% to 5% of the population. The major AITDs include Graves disease (GD) and Hashimoto's thyroiditis (HT); although these diseases contrast clinically, their pathogenesis involves shared immunogenetic mechanisms. Genetic data point to the involvement of both shared and unique genes. Among the shared susceptibility genes, HLA-DRβ1-Arg74 (human leukocyte antigen DR containing an arginine at position β74) confers the strongest risk. Recent genome-wide analyses have revealed new putative candidate genes. Epigenetic modulation is emerging as a major mechanism by which environmental factors interact with AITD susceptibility genes. Dissecting the genetic-epigenetic interactions underlying the pathogenesis of AITD is essential to uncover new therapeutic targets. © 2014 by Annual Reviews. All rights reserved.


Frucht S.J.,Mount Sinai Medical Center
Movement Disorders | Year: 2013

The definition of dystonia has been a subject of much debate and controversy for the last century. In this paper, a practical definition of dystonia for the movement disorders expert is presented, based on a new algorithm. © 2013 Movement Disorder Society.


Tomer Y.,Mount Sinai Medical Center
Thyroid : official journal of the American Thyroid Association | Year: 2010

BACKGROUND: Autoimmune thyroid diseases (AITD), including Graves' disease and Hashimoto's thyroiditis, arise due to complex interactions between environmental and genetic factors. There are sound data coming from epidemiological, family, and twin studies demonstrating a strong genetic influence on the development of AITD. In this review we summarize the new findings on the genetic susceptibility to AITD focusing on emerging mechanisms of susceptibility. SUMMARY: Candidate gene analysis, whole-genome linkage screening, genome-wide association studies, and whole-genome sequencing are the major technologies that have advanced this field, leading to the identification of at least seven genes whose variants have been associated with AITD. One of the major ones is the HLA-DR gene locus. Recently, it was shown that substitution of the neutral amino acids Ala or Gln with arginine at position beta 74 in the HLA-DR peptide-binding pocket is key to the etiology of both Graves' disease and Hashimoto's thyroiditis. Several other genes have also been shown to confer susceptibility to AITD. These can be classified into two groups: (i) immune regulatory genes (cytotoxic T lymphocyte-associated protein 4, CD40, protein tyrosine phosphatase-22, and CD25) and (ii) thyroid-specific genes (thyroglobulin and thyrotropin receptor genes). The influence of individual genes on the development of AITD when assessed in a population appears to be weaker than would be expected from the data showing strong genetic susceptibility to AITD. Two possible mechanisms explaining this discrepancy are gene-gene interactions and subset effects. CONCLUSIONS: Significant progress has been made in our understanding of the immunogenetic mechanisms leading to thyroid autoimmunity. For the first time we are beginning to unravel these mechanisms at the molecular level. It is hoped that these new data will be translated into novel therapies and prevention strategies in AITD, such as costimulatory blockade.


Shapiro J.S.,Mount Sinai Medical Center
American journal of public health | Year: 2011

Public health relies on data reported by health care partners, and information technology makes such reporting easier than ever. However, data are often structured according to a variety of different terminologies and formats, making data interfaces complex and costly. As one strategy to address these challenges, health information organizations (HIOs) have been established to allow secure, integrated sharing of clinical information among numerous stakeholders, including clinical partners and public health, through health information exchange (HIE). We give detailed descriptions of 11 typical cases in which HIOs can be used for public health purposes. We believe that HIOs, and HIE in general, can improve the efficiency and quality of public health reporting, facilitate public health investigation, improve emergency response, and enable public health to communicate information to the clinical community.

Loading Mount Sinai Medical Center collaborators
Loading Mount Sinai Medical Center collaborators